Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 7Breast Neoplasms 6Ovarian Neoplasms 5Stomach Neoplasms 4Colonic Neoplasms 4Rectal Neoplasms 3Lung Neoplasms 3Neoplasm Metastasis 2Melanoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Zollinger-Ellison Syndrome 1Vipoma 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Somatostatinoma 1Renal Insufficiency 1Prostatic Neoplasms 1Pheochromocytoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Failure 1

Interventions

pembrolizumab 10Paclitaxel 8Taxes 6Nivolumab 4Cyclophosphamide 4Cisplatin 4Carboplatin 4Polymerase Chain Reaction 3Irinotecan 3Interleukin-12 Subunit p35 3Docetaxel 3Bevacizumab 3sargramostim 2lenvatinib 2aldesleukin 2aflibercept 2Trastuzumab 2SS1(dsFv)PE38 2Radiotherapy 2Psychiatric Rehabilitation 2Methods 2Interleukin-12 2Gene Expression Profiling 2Gemcitabine 2Filgrastim 2Early Intervention, Educational 2Capecitabine 2Albumin-Bound Paclitaxel 2veliparib 1tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × veliparib × Gastrointestinal × Clear all
NCT01233505 2014-04-02

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Terminated
16 enrolled
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡